polycythaemia neonatal management clinical guideline v1.0
TRANSCRIPT
Polycythaemia Neonatal Management Clinical Guideline
V1.0
June 2021
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 2 of 14
Summary
Infant identified as at risk of
polycythaemia with one sign or symptom
Capillary Haematocrit
identified (Hct) >70%
Venous Full Blood Count sample
Asymptomatic Symptomatic
Venous Hct 75%
Venous Hct 65-70%
Consider Partial Exchange transfusion via UVC/UAC and peripheral venous line Nil by Mouth until Hct < 65% then as per high risk feeding regime Monitor urine output and fluid balance and investigate further causes Regular electrolytes and bilirubin and plot on appropriate chart 6-12 hourly FBC depending on severity of symptoms
Venous Hct >70%
Venous Hct 65-70%
Venous Hct >70%
Capillary Hct identified >65% and
one sign or symptom
Observations 4 hourly for 12 hours. 2 x pre feed blood sugars. Ensure adequate hydration, urine output. Observe for signs of jaundice. Repeat FBC after 12 hours.
Observations 4 hourly for 12 hours 2 x pre feed blood sugars Ensure adequate hydration, increase fluid intake to one day ahead if tolerated. Observing adequate urine output Observe for signs of jaundice
Admit to NNU Neonatal Unit IV dextrose ECG Monitoring High risk feeding regime Fluid balance Monitor electrolytes and bilirubin 12 hourly FBC until asymptomatic and Hct <70%
If worsening symptoms
Symptomatic or worsening FBC
Signs or Symptoms
Hypoglycaemia requiring treatment with IV Dextrose
Jaundice requiring phototherapy
CNS symptoms with unknown cause - Irritability, lethargy, seizure
Poor feed absorption - not tolerating hourly feeds, bilious aspirates
Urine output < 1ml/kg/hr
Infants at risk
Infant of diabetic mother
Prolonged delayed cord clamping >2 mins
Twin to Twin transfusion
Intrauterine growth restriction (IUGR)
Cord pH <7.0
Large for gestational age >98th centile
Chromosomal anomalies such as Trisomy 21, 18 and 13
Severe Preeclampsia
4 hours NEWS observations. Ensure adequate hydration, urine output. Observe for signs of jaundice.
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 3 of 14
1. Aim/Purpose of this Guideline
1.1. To assist staff with identifying possible causes for, and infants at risk of Neonatal Polycythaemia. This guidance is for the management of these infants in order to prevent further complications.
2. The Guidance
Polycythaemia is defined as a venous packed cell volume/haematocrit (Hct) of over 65%. This condition affects approximately 1-5% of newborns in the postnatal period. Many affected infants are asymptomatic and the characteristic clinical features and related complications are thought to occur as a result of hyperviscosity. It is however important to note that not all polycythaemic infants suffer from hyperviscosity. Hyperviscosity can result in serious clinical consequences due to reduced blood flow to organs leading to poor tissue perfusion and possible microthrombus formation. Sampling variability can occur when measuring haematocrit and therefore a venous, free flowing sample is gold standard and must always be obtained to confirm diagnosis. The treatment of polycythaemia is also variable because it is uncertain whether intervention affects long-term outcome and may be associated with some gastrointestinal morbidity. Dehydration is also a common case of polycythaemia when identified into the 2nd -3rd day of life. This should be corrected and treated accordingly then haematocrit reviewed subsequently. 2.1. Infants at risk of Polycythaemia
Infant of diabetic mother
Delayed Cord clamping with other risk factors
Twin to Twin transfusion
Data Protection Act 2018 (General Data Protection Regulation – GDPR) Legislation
The Trust has a duty under the DPA18 to ensure that there is a valid legal basis to process personal and sensitive data. The legal basis for processing must be identified and documented before the processing begins. In many cases we may need consent; this must be explicit, informed and documented. We cannot rely on opt out, it must be opt in.
DPA18 is applicable to all staff; this includes those working as contractors and providers of services.
For more information about your obligations under the DPA18 please see the Information Use Framework Policy or contact the Information Governance Team [email protected]
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 4 of 14
Intrauterine growth restriction (IUGR)
Intrapartum Hypoxia
Large for gestational age
Chromosomal anomalies such as Trisomy 21, 18 and 13
Maternal Preeclampsia
Endocrine abnormalities such as hypothyroidism, congenital adrenal hyperplasia
2.2. Signs and Symptoms
Many polycythaemic infants will be asymptomatic and only appear plethoric on examination. Polycythaemic infants who are developing hyperviscocity may present with these signs and symptoms over the first 24 hours;
Respiratory distress +/- Apnoea
Cyanosis
Cardiopulmonary complications such as tachycardia, Persistent Pulmonary Hypertension of the Newborn (PPHN), cardiomegaly
Gastrointestinal problems such as poor feeding, vomiting, Necrotising enterocolitis (NEC)
Neurological complications such as lethargy, irritability, jitteriness, seizures
Persistent hypoglycaemia requiring high GIR
Hypocalcaemia
Jaundice requiring more than standard phototherapy
Renal complications such as decreased urine output, renal vein thrombosis
Coagulation difficulties such as thrombocytopenia
2.3. Investigations Haematocrit in term infants, who appear clinically well, should not be measured routinely, including those with risk factors. However, if signs or symptoms occur then the following investigations should be undertaken:
Full maternal and infant history to identify predisposing factors
Systematic clinical examination including: respiratory status, capillary refill time, femorals and bowel sounds
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 5 of 14
Identify any risk of dehydration such as significant weight loss in first 5 days
In any infant identified to be at risk of polycythaemia and presenting with one of the stated signs or symptoms they must have a venous full blood count (FBC) sent to the laboratory with a full electrolyte sample (green bottle) and blood gas for blood glucose
The diagnosis of polycythaemia can only be made from a venous Hct. It is important to acknowledge that many infants may present with symptoms similar to those attributed to polycythaemia with hyperviscosity and that other aetiologies should also be considered. Symptoms of hyperviscosity are likely to be severe and persistent.
2.4. Management 2.4.1. Asymptomatic and Symptomatic Management
2.4.1.1. Asymptomatic Infants with Hct 65-70%
Clinical polycythaemia management not required
Ensure adequate hydration by monitoring oral intake and seeking prompt support from infant feeding team if required
Observing adequate urine output
Observe for signs of jaundice
2.4.1.2. Asymptomatic Infants with Hct 70-75%
Observations 4 hourly for 12 hours, following flowchart if any symptoms occur
Two pre-feed blood sugars and manage as per Hypoglycaemia guideline if required
Ensure adequate hydration by monitoring oral intake and seeking prompt support from infant feeding team if required
Observe adequate urine output
Observe for signs of jaundice
Repeat venous FBC after 12 hours
2.4.1.3. Symptomatic Infants with Hct 65-70%- see decision making flowchart
Observations 4 hourly for 12 hours, following flowchart if any further symptoms occur
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 6 of 14
Two pre-feed blood sugars and manage as per Hypoglycaemia guideline if required
Ensure adequate hydration by monitoring oral intake and seeking prompt support from infant feeding team if required. Increase fluid intake to one day ahead, pass nasogastric tube if unable to maintain volumes orally
Observing adequate urine output
Observe for signs of jaundice
2.4.1.4. Symptomatic infants with Hct >70%- see decision making flowchart
Consider admitting to Neonatal Unit and commence IV dextrose for 24 hours minimum (can be fed a day ahead if mild symptoms only- e.g. jaundice only requiring phototherapy, one off hypoglycaemia)
ECG Monitoring
High risk feeding regime
Monitor fluid balance and urine output
Monitor electrolytes and bilirubin and plot on appropriate chart
12 hourly FBC and electrolytes until asymptomatic and HCT <70%
If worsening symptoms such as persistent hypoglycaemia or respiratory distress despite intravenous fluids, to discuss with Neonatal Consultant about performing a partial exchange transfusion
2.4.1.5. Symptomatic or Asymptomatic infants with Hct >75%-
see decision making flowchart
Consider Partial Exchange transfusion via Umbilical Venous Catheter/Umbilical Arterial Catheter and peripheral venous line
Consideration should be given to investigation of other causes of polycythaemia especially if persistent/worsening symptoms
Nil by mouth until Hct < 65% then as per high risk feeding regime
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 7 of 14
Monitor urine output and fluid balance
Regular electrolytes and bilirubin, and plot on appropriate chart
6-12 hourly FBC depending on severity of symptoms 2.4.2. Partial Exchange Transfusion
2.4.2.1. The accepted treatment of polycythaemia is partial exchange transfusion (PET), however it should be noted that PET has not been shown to have beneficial effects on long term outcomes and due to associated complications should therefore be discussed with the Neonatal Consultant before being undertaken(1). Partial Exchange Transfusion in preterm infants is higher risk and must always be discussed with the Neonatal Consultant; with a cranial ultrasound pre-procedure for all infants <34 weeks CGA.
2.4.2.2. PET involves slowly removing some of the blood volume and replacing the withdrawn blood with fluids to help dilute the red blood cell concentration. Partial exchange transfusion must take place in an intensive care setting with continuous monitoring, following informed parental consent.
2.4.2.3. Vascular access will be required for the transfusion to
take place ideally a UAC/UVC (blood out) and a peripheral venous line (saline in).
2.4.2.4. Volume to be exchanged is 15ml/kg of blood with an at
least 15ml/kg 0.9% Sodium Chloride, this should be performed in 5ml/kg aliquots over 30 minutes (90 minutes total time). Ensure baby’s thermal care is maintained during the procedure (2,3).
2.4.2.5. Equipment
Cardio-respiratory monitoring equipment, including saturation and blood pressure monitoring
Volumetric pump
Sterile gowns, gloves and pack
Closed system urine bag/ paediatric waste urine bag and extension set
Assorted lure lock syringes, 3 way taps and extension sets depending on access
Exchange transfusion observation and in/out chart
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 8 of 14
Clock
2.4.2.6. Procedure
Use aliquots of 5 mL/kg; withdraw blood and infuse an equal amount of saline
First remove aliquot of blood in volume as above. Always ensure blood is removed first
This first aliquot withdrawn should be sent for FBC, U&E, LFT, phosphate, SBR
Hct, Calcium, magnesium, glucose and clotting
Stop partial exchange transfusion if infant’s condition suddenly deteriorates – but always
Leave infant’s blood volume in balance
Sudden deterioration maybe be due to underlying condition, the procedure or an adverse reaction to transfusion
Blood glucose should be measured prior to and after procedure
2.4.2.7. Complications of PET
Gastrointestinal disturbances (e.g. abdominal distention, vomiting)
Necrotising enterocolitis
Electrolyte disturbances e.g. Hypoglycaemia
Infection
2.4.2.8. Procedure: Nursing roles and Responsibilities
Do not interrupt the phototherapy during exchange.
Ensure parents are fully informed and have consented to procedure
Ensure baby is in the Intensive care room and begin monitoring heart rate, respirations, blood pressure, oxygen saturations and temperature. Record baseline observations prior to procedure and then every 15 mins throughout the exchange
Maintain neutral thermal environment, ideally in open cot
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 9 of 14
Baby must be nil by mouth prior to an exchange, leave NGT on free drainage
Administer IV fluids as prescribed and observe all lines as per policy
Record pre transfusion blood glucose and then following the procedure
Ensure day 0 blood spot sample has been taken and labelled
Use a chart to document in and out volumes
All clinical staff should be ready to start simultaneously and should have no other workload ie 1:1 care
All lines should be monitored for extravasation, blanching, erythema, leakage, and oedema. They should be recorded as per Trust policy
On completion the lines should be flushed with saline to maintain patency
Inform parents that procedure has been completed
Documentation - contemporaneously documented, accurate fluid balances, sample taken, observations, and any untoward reactions and outcomes reported appropriately
2.4.2.9. Nursing care post procedure
Monitor and record blood glucoses at 1,2 and 4 hours post transfusion
Observe for any distension, vomiting, and blood in stools
Urinalysis
Repeat FBC 6 hours post PET
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 10 of 14
3. Monitoring compliance and effectiveness
Element to be monitored
Compliance with policy/ key changes to practice
Lead Neonatal Guidelines Lead and Author
Tool Adherence to guidelines will be monitored as part of the ongoing audit process on a Word or Excel template
Frequency As dictated by audit findings
Reporting arrangements
Neonatal Guidelines Group
Acting on recommendations and Lead(s)
Neonatal Guidelines Lead and Author
Change in practice and lessons to be shared
Required changes to practice will be identified and actioned within 3 months, immediately if required. A lead member of the team will be identified to take each change forward where appropriate. Lessons will be shared with all the relevant staff/stakeholders
4. Equality and Diversity
4.1. This document complies with the Royal Cornwall Hospitals NHS Trust service Equality and Diversity statement which can be found in the 'Equality, Inclusion & Human Rights Policy' or the Equality and Diversity website.
4.2. Equality Impact Assessment
The Initial Equality Impact Assessment Screening Form is at Appendix 2.
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 11 of 14
Appendix 1. Governance Information
Document Title Polycythaemia Neonatal Management Clinical Guideline V1.0
This document replaces (exact title of previous version):
New Document
Date Issued/Approved: January 2021
Date Valid From: June 2021
Date Valid To: June 2024
Directorate / Department responsible (author/owner):
Jenna Julian; Neonatal Nurse
Contact details: 01872 252667
Brief summary of contents Guideline on the management of neonates with suspected or confirmed polycythaemia
Suggested Keywords: Neonatal Polycythaemia, Exchange Transfusion
Target Audience RCHT CFT KCCG
Executive Director responsible for Policy:
Medical Director
Approval route for consultation and ratification:
Neonatal Guidelines Group
General Manager confirming approval processes
Mary Baulch
Name of Governance Lead confirming approval by specialty and care group management meetings
Caroline Amukusana
Links to key external standards None Required
Related Documents:
1. Dempsey, E. M., Barrington, K. (2006) Short and long term outcomes following partial exchange transfusion in the polycythaemic newborn: a systematic review. Arch Dis Child Fetal Neonatal Ed. 91(1).
2. Ghoshal, S., Matthews, Y. Y. (2011) Polycythaemia and Hyperviscosity in Newborn.
3. ADHD (2012) Newborn Clinical services guideline- Partial Exchange Transfusion.
4. Garcia- Prat, J.A. (2019) Neonatal Polycythemia.
Training Need Identified? No
Publication Location (refer to Policy on Policies – Approvals and Ratification):
Internet & Intranet Intranet Only
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 12 of 14
Document Library Folder/Sub Folder
Clinical/ Neonatal
Version Control Table
Date Version
No Summary of Changes
Changes Made by (Name and Job
Title) January 2021
V1.0 Initial issue Jenna Julian; Neonatal Nurse
All or part of this document can be released under the Freedom of Information
Act 2000
This document is to be retained for 10 years from the date of expiry.
This document is only valid on the day of printing
Controlled Document
This document has been created following the Royal Cornwall Hospitals NHS Trust
Policy for the Development and Management of Knowledge, Procedural and Web
Documents (The Policy on Policies). It should not be altered in any way without the
express permission of the author or their Line Manager.
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 13 of 14
Appendix 2. Equality Impact Assessment
Section 1: Equality Impact Assessment Form
Name of the strategy / policy /proposal / service function to be assessed Polycythaemia Neonatal Management Clinical Guideline V1.0
Directorate and service area: Neonatal
Is this a new or existing Policy? New
Name of individual/group completing EIA Neonatal Guidelines Group
Contact details: 01872 252667
1. Policy Aim Who is the strategy / policy / proposal / service function aimed at?
Medical and Nursing staff caring for Neonates within Maternity and Neonates
2. Policy Objectives Provide a framework for assessment and management of infants with symptomatic and asymptomatic polycythaemia.
3. Policy Intended Outcomes
To improve the well-being of patients by offering the appropriate management.
4. How will you measure the outcome?
Audit/ Multidisciplinary team weekly discussion/ incidents/ risk management
5. Who is intended to benefit from the policy?
Patients and their families.
6a). Who did you consult with?
b). Please list any groups who have been consulted about this procedure.
Workforce Patients Local groups
External organisations
Other
x
Please record specific names of groups:
Neonatal Guidelines Group
c). What was the outcome of the consultation?
Approved- 20th January 2021
Polycythaemia Neonatal Management Clinical Guideline V1.0 Page 14 of 14
7. The Impact Please complete the following table. If you are unsure/don’t know if there is a negative impact you need to repeat the consultation step. Are there concerns that the policy could have a positive/negative impact on:
Protected Characteristic
Yes No Unsure Rationale for Assessment / Existing Evidence
Age X
Sex (male, female non-binary, asexual etc.)
X
Gender reassignment X
Race/ethnic communities /groups X
Any information provided should be in an accessible format for the parent/carer needs – i.e. available in different languages if required/access
to an interpreter if required
Disability (learning disability, physical disability, sensory impairment, mental health problems and some long term health conditions)
X
Those parent/carers with any identified additional needs will be referred for additional support as
appropriate- i.e. to the Liaison team or for specialised equipment.
Written information will be provided in a format to meet the family’s needs e.g. easy read, audio etc
Religion/ other beliefs X
All staff should be aware of any beliefs that may impact on the decision to treat
Marriage and civil partnership X
Pregnancy and maternity X
Sexual orientation (bisexual, gay,
heterosexual, lesbian) X
If all characteristics are ticked ‘no’, and this is not a major working or service change, you can end the assessment here as long as you have a robust rationale in place.
I am confident that section 2 of this EIA does not need completing as there are no highlighted risks of negative impact occurring because of this policy.
Name of person confirming result of initial impact assessment:
Neonatal Guidelines Group
If you have ticked ‘yes’ to any characteristic above OR this is a major working or service change, you will need to complete section 2 of the EIA form available here: Section 2. Full Equality Analysis For guidance please refer to the Equality Impact Assessments Policy (available from the document library) or contact the Human Rights, Equality and Inclusion Lead [email protected]